ROBIN: a randomised, double-masked, placebo-controlled Phase IIa study of the AOC3 inhibitor BI 1467335 in diabetic retinopathy

2024 . Nguyen, Quan | Ehlers, Justis | Boyer, David S. | Jin, Xidong | Giani, Andrea | Ehrlich, Michael S. | On behalf of the ROBIN study investigators | Brucker, Alexander | Hu, Allen | Fawzi, Amani | Antoszyk, Andrew | Berger, Brian | Jhaveri, Chirag | Bailey, Claire | Brown, David | Kunimoto, Derek | Ghanchi, Faruque | Bandello, Francesco | Menon, Geeta | Sen, Harsha | Talks, James | Figueira, João | Barranco, Jose Juan Escobar | Donate Lopez, Juan | Habib, Maged | Erke, Maja Gran | Weger, Martin | Cunningham, Matthew | Varano, Monica | Manjunatha, Nonavinakere | Hahn, Paul | Calvo, Pilar | Dugel, Pravin | Maturi, Raj | Rosen, Richard | Silva, Rufino | Pagliarini, Sergio | Sivaprasad, Sobha | Androudi, Sofia | Patel, Sunil | Vall d’Hebron University Hospital | CHLC - Hospital Santo António dos Capuchos